JP Morgan Chase
DNTH icon

JP Morgan Chase’s Dianthus Therapeutics DNTH Stock Holding History

JP Morgan Chase’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$183K Buy
+2,300
New +$133K ﹤0.01% 5518

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase's DNTH Position: Q1 2026 in Review

JP Morgan Chase reduced its Dianthus Therapeutics (DNTH) stake by 25% in Q1 2026, selling an estimated $620K and leaving 31,938 shares worth $2.54M. The position accounts for ﹤0.01% of the portfolio, ranked #3926.

JP Morgan Chase first reported a position in DNTH in Q3 2018 and has held it in 31 quarters since. The position peaked at $5.59M in Q1 2021. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • JP Morgan Chase held 31,938 shares of Dianthus Therapeutics worth $2.54M as of Q1 2026.
  • JP Morgan Chase sold 10,701 Dianthus Therapeutics shares in Q1 2026, an estimated $620K.
  • Dianthus Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3926 holding.
  • JP Morgan Chase first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • JP Morgan Chase's Dianthus Therapeutics position peaked at $5.59M in Q1 2021.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.